Medicines planning
51 results
Applied filters
Biosimilar and key generic medicines – December 2025 update
10 December 2025An update about biosimilar and key generic medicines to support system planning and mobilisation.
Preparing to use aflibercept 2mg biosimilar
10 December 2025Aflibercept 2mg biosimilars for use in ophthalmology are expected in December 2025 for NHS use. We offer general information and implementation advice.
Preparing to use denosumab 60mg biosimilar
5 December 2025Biosimilars of denosumab 60mg (Prolia) are expected soon. We offer general information and implementation advice.
New Medicines News
4 December 2025New Medicines News is produced by the SPS Horizon Scanning Service. It highlights recent new product launches and significant medicines regulatory changes.
The licence and supporting evidence for aflibercept biosimilars
28 November 2025Aflibercept 2mg biosimilars Afqlir, Eydenzelt, Yesafili and Vgenfli are expected in December 2025 for NHS use. Learn about supporting evidence and differences.
New Product Evaluations
25 November 2025A list of new product evaluations that are freely available to NHS staff.
The licence and supporting evidence for omalizumab biosimilar
14 November 2025We highlight evidence for licensed omalizumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Xolair).
Preparing to use denosumab 120mg biosimilar
14 November 2025Biosimilars of denosumab 120mg (Xgeva) are expected soon. We offer general information and implementation advice.
Preparing to use ranibizumab biosimilar
5 November 2025Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
The licence and supporting evidence for ranibizumab biosimilars
5 November 2025Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence